Inhibition of serum phospholipase-A₂ in acute pancreatitis by pharmacological agents in vitro

References

• Dennis E A. Modification of the arachidonic acid cascade through phospholipase-A2 dependent mechanisms. Adv Prostaglandin Thromboxane Leukotriene Res 1990; 20: 217–23
   PubMedGoogle Scholar
• Anderson B O, Moore E E, Banerjee A. Phospholipase-A2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res 1994; 56: 199–205
   PubMed Web of Science ®Google Scholar
• Schmidt H, Creutzfeldt W. The possible role of phospholipase-A in the pathogenesis of acute pancreatitis. Scand J Gastroenterol 1969; 4: 39–48
   PubMed Web of Science ®Google Scholar
• Nevalainen T J. Phospholipase-A2 in acute pancreatitis. Scand J Gastroenterol 1988; 23: 897–904
   PubMed Web of Science ®Google Scholar
• Holm B A, Keicher L, Liu M Y, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991; 71: 317–21
   PubMed Web of Science ®Google Scholar
• Rao K N. Pathophysiology of pancreatitis: the role of prostaglandins. Prostaglandins 1993; 45: 309–13
   PubMed Web of Science ®Google Scholar
• Gross V, Leser H G, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines—new aspects of the pathophysiology and assessment of severity of acute pancreatitis?. Hepatogastroenterology 1993; 40: 522–30
   PubMedGoogle Scholar
• Schröder T, Kivilaakso E, Kinnunen P K, Lempinen M. Serum phospholipase A2 in human acute pancreatitis. Scand J Gastroenterol 1980; 15: 633–6
   PubMed Web of Science ®Google Scholar
• Büchler M, Malfertheiner P, Schadlich H, Nevalainen T J, Friess H, Beger H G. Role of phospholipase-A2 in human acute pancreatitis. Gastroenterology 1989; 97: 1521–6
   PubMed Web of Science ®Google Scholar
• Kaiser E, Chiba P, Zaky K. Phospholipases in biology and medicine. Clin Biochem 1990; 23: 349–70
   PubMed Web of Science ®Google Scholar
• Nevalainen T J, Grönroos J M, Kortesuo P T. Pancreatic and synovial type phospholipase A2 in serum samples from patients with severe acute pancreatitis. Gut 1993; 34: 1133–6
   PubMed Web of Science ®Google Scholar
• Nevalainen T J. Serum phospholipase A2 in inflammatory diseases. Clin Chem 1993; 39: 2453–9
   PubMed Web of Science ®Google Scholar
• Vadas P, Pruzanski W, Stefanski E. Extracellular phospholipase-A2: causative agent in circulatory collapse of septic shock?. Agents Actions 1988; 24: 320–5
   PubMedGoogle Scholar
• Pruzanski W, Vadas P, Kim J, Jacobs H, Stefanski E. Phospholipase-A2 activity associated with synovial fluid cells. J Rheumatol 1988; 15: 791–4
   PubMed Web of Science ®Google Scholar
• Tykkä H T, Vaittinen E J, Mahlberg K L, et al. A randomized double-blind study using CaNa2EDTA, a phospholipase-A2 inhibitor, in the management of human acute pancreatitis. Scand J Gastroenterol 1985; 20: 5–12
   PubMed Web of Science ®Google Scholar
• Imrie C W, Benjamin I S, Ferguson J C, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65: 337–41
   PubMed Web of Science ®Google Scholar
• Puolakkainen P, Paananen A, Kaarne M, Kuusi T, Lempinen M, Schröder T. Aprotinin and Na2CaEDTA in experimental hemorrhagic pancreatitis in pigs. Scand J Gastroenterol 1987; 22: 35–41
   PubMed Web of Science ®Google Scholar
• Schröder T, Lempinen M, Nordling S, Kinnunen P K. Chlorpromazine treatment of experimental acute fulminant pancreatitis in pigs. Eur Surg Res 1981; 13: 143–51
   PubMed Web of Science ®Google Scholar
• Yang C Y, Chang-Chien C S, Liaw Y F. Controlled trial of protease inhibitor gabexate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698–700
   PubMed Web of Science ®Google Scholar
• Scheuer W. Phospholipase-A2—regulation and inhibition. Klin Wochenschr 1989; 67: 153–9
   PubMedGoogle Scholar
• Niederau C, Schulz H U. Current conservative treatment of acute pancreatitis: evidence from animal and human studies. Hepatogastroenterology 1993; 40: 538–49
   PubMedGoogle Scholar
• Mäkelä A, Kuusi T, Somerharju P, Schröder T. A simple isotopic assay method for human serum phospholipase-A2 activity. Scand J Clin Lab Invest 1987; 47: 529–34
   PubMed Web of Science ®Google Scholar
• Therapeutic drugs 1–2, v. 43rd ed., C Collery. Churchill Livingstone, London 1991
   Google Scholar
• Narang P K, Wilder R, Chatterji D C, Yeager R L, Gallelli J F. Systemic bioavaibility and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following “high-dose” pulse administration. Biopharmacol Drug Dispos 1983; 4: 233–48
   PubMed Web of Science ®Google Scholar
• Petersen M C, Nation R L, McBride W G, Ashley J J, Moore R G. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol 1983; 25: 643–50
   PubMed Web of Science ®Google Scholar
• Toothaker R D, Craig W A, Welling P G. Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. J Pharm Sci 1982; 71: 1182–5
   PubMed Web of Science ®Google Scholar
• Franson R C, Eisen D, Jesse R, Lanni C. Inhibition of highly purified mammalian phospholipases A2 by non-steroidal anti-inflammatory agents. Modulation by calcium ions. Biochem J 1980; 186: 633–6
   PubMed Web of Science ®Google Scholar
• Ohuchi K, Watanabe M, Numajiri N, Tsurufuji S. Phospholipase-A2 activity in carragheenin-induced inflammatory tissue of rats. Biochem Pharmacol 1982; 31: 2993–8
   PubMed Web of Science ®Google Scholar
• Vadas P, Stefanski E, Pruzanski W. Potential therapeutic efficacy of inhibitors of human phospholipase-A2 in septic shock. Agents Actions 1986; 19: 194–202
   PubMedGoogle Scholar
• Yamamoto S, Nakaki T, Nakadate T, Kato R. Insulinotropic effects of exogenous phospholipase-A2 and C in isolated pancreatic islets. Eur J Pharmacol 1982; 86: 121–4
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kato T, Matsumoto K, Yoshida T. Anti-inflammatory action of thielocin A1 beta, a group II phospholipase-A2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation 1993; 17: 107–19
   PubMed Web of Science ®Google Scholar
• Seeman P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 1972; 24: 583–655
   PubMed Web of Science ®Google Scholar
• Kunze H, Nahas N, Traynor J R, Wurl M. Effects of local anaesthetics on phospholipases. Biochim Biophys Acta 1976; 441: 93–102
   PubMed Web of Science ®Google Scholar
• Lindahl M, Tagesson C. Selective inhibition of group II phospholipase-A2 by quercetin. Inflammation 1993; 17: 573–82
   PubMed Web of Science ®Google Scholar
• Fradin A, Rothhut B, Poincelot-Canton B, Errasfa M, Russo-Marie F. Inhibition of eicosanoid and PAF formation by dexamethasone in rat inflammatory polymorphonuclear neutrophils may implicate lipocortin “s”. Biochim Biophys Acta 1988; 963: 248–57
   PubMed Web of Science ®Google Scholar
• Mentz P, Giessler C, Forster W. Evidence for a direct inhibitory effect of glucocorticoids on the activity of phospholipase-A2 as a further possible mechanism of some actions of steroidal antiinflammatory drugs. Pharmacol Res Commun 1980; 12: 817–27
   PubMedGoogle Scholar
• Kato N, Halprin K M, Matsuo S, Taylor J R. Dexamethasone directly inhibits snake venom phospholipase-A. Biochem Biophys Res Commun 1985; 130: 761–7
   PubMed Web of Science ®Google Scholar
• Das U N, Padma M, Sagar P S, Ramesh G, Koratkar R. Stimulation of free radical generation in human leukocytes by various agents including tumor necrosis factor is a calmodulin dependent process. Biochem Biophys Res Commun 1990; 167: 1030–6
   PubMed Web of Science ®Google Scholar
• van den Bosch H, Schalkwijk C, Pfeilschifter J, Marki F. The induction of cellular group II phospholipase-A2 by cytokines and its prevention by dexamethasone. Adv Exp Med Biol 1992; 318: 1–10
   PubMedGoogle Scholar
• Vervoordeldonk M J, Schalkwijk C G, Vishwanath B S, Aarsman A J, van den Bosch H. Levels and localization of group II phospholipase-A2 and annexin I in interleukin- and dexamethasone-treated rat mesangial cells: evidence against annexin mediation of the dexamethasone-induced inhibition of group II phospholipases A2. Biochim Biophys Acta 1994; 1224: 541–50
   PubMed Web of Science ®Google Scholar
• Nagai S, Sugiyama S, Ozawa T. Classification of B- blocking agents by their inhibitory effects on phospholipase-Activity. Jpn Circ J 1986; 50: 238–41
   PubMedGoogle Scholar
• Carlier M B, Laurent G, Tulkens P. In vitro inhibition of lysosomal phospholipases by aminoglycoside antibiotics: a comparative study. Arch Toxicol Suppl 1984; 7: 282–5
   PubMedGoogle Scholar
• Jain M K, Jahagirdar D V. Action of phospholipase-A2 on bilayers. Effect of inhibitors. Biochim Biophys Acta 1985; 814: 319–26
   PubMed Web of Science ®Google Scholar
• Pruzanski W, Greenwald R A, Street I P, Laliberte F, Stefanski E, Vadas P. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44: 1165–70
   PubMed Web of Science ®Google Scholar
• Kiviniemi H, Rämö O J, Stählberg M, Kairaluoma M I. Indomethacin in canine acute hemorrhagic pancreatitis. Res Exp Med Berl 1988; 188: 35–40
   PubMedGoogle Scholar
• Wildenhain P M, Melhem M F, Birsic W I, Sell H W, Rao K N. Acute hemorrhagic pancreatitis in mice: improved survival after indomethacin administration. Digestion 1989; 44: 41–51
   PubMed Web of Science ®Google Scholar